In oncology, crispr has revolutionized drug target discovery & validation
However, these screens are performed in cell-line models with unknown translability to the clinic.
However, these screens are performed in cell-line models with unknown translability to the clinic.
“We can't ethically conduct these experiments [screens] in people, but in a way, life has performed these experiments for us”
- Jennifer Doudna
Our proprietary technology identifies novel drug targets whose downregulation leads to cancer death. Derived from patient samples, these findings are more likely to translate into clinical success.
In the ‘Mother’s Nature’ experiment, clinically successful drug targets like MEK1, PARP or PD-L1 display different to expected levels of deleterious mutations but only in tissues where their respective inhibitors produce favorable clinical responses.
Purpose-built patient
tumor database
Tissue types
of mutations
Gene-altering
mutations
Proprietary
Gordion can identify novel drug targets ‘invisible’ to cell line-based assays across any indication.
To learn more about the Gordion Platform, explore our case studies.
Download PDF
